Diarrhea News and Research

Latest Diarrhea News and Research

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

Global access to safe drinking water increased, sanitation lagging behind, WHO-UNICEF report finds

Global access to safe drinking water increased, sanitation lagging behind, WHO-UNICEF report finds

Lipitor 80 mg may help reduce risk of major cardiovascular events in high-risk patients

Lipitor 80 mg may help reduce risk of major cardiovascular events in high-risk patients

GAVI calls meeting with existing, potential donors

GAVI calls meeting with existing, potential donors

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

NDA for BYDUREON: FDA issues complete response letter

NDA for BYDUREON: FDA issues complete response letter

FDA looks into supply chain of black and red pepper as part of Salmonella Montevideo investigation

FDA looks into supply chain of black and red pepper as part of Salmonella Montevideo investigation

Ipsen commences dosing in two BIM 23A760 phase II studies for neuroendocrine tumors and acromegaly

Ipsen commences dosing in two BIM 23A760 phase II studies for neuroendocrine tumors and acromegaly

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

First use of prenatal MRI to detect often-misdiagnosed CCD

First use of prenatal MRI to detect often-misdiagnosed CCD

IBS patients are at no greater risk of having polyps, colon cancer than healthy people undergoing colonoscopies

IBS patients are at no greater risk of having polyps, colon cancer than healthy people undergoing colonoscopies

Researchers in Canada discover novel oncolytic viral therapy against prostate cancer

Researchers in Canada discover novel oncolytic viral therapy against prostate cancer

Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive

Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive

ITCH gene causes multisystem autoimmune disorder

ITCH gene causes multisystem autoimmune disorder

Tetanus, hepatitis vaccination campaign launched in Chile amid fears of disease outbreaks

Tetanus, hepatitis vaccination campaign launched in Chile amid fears of disease outbreaks

Positive Phase 2 data from Nektar Therapeutics' NKTR-102 study in women with platinum-resistant ovarian cancer

Positive Phase 2 data from Nektar Therapeutics' NKTR-102 study in women with platinum-resistant ovarian cancer

Salmonella Montevideo outbreak: FDA investigates Daniele International's pepper supply chain

Salmonella Montevideo outbreak: FDA investigates Daniele International's pepper supply chain

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.